NA
CRSP icon

NewEdge Advisors’s CRISPR Therapeutics CRSP Stock Holding History

NewEdge Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$169K Sell
3,553
-5
-0.1% -$264 ﹤0.01% 2644
2025
Q4 		$187K Sell
3,558
-6,956
-66% -$417K ﹤0.01% 2594
2025
Q3 		$681K Buy
10,514
+1,937
+23% +$111K ﹤0.01% 1632
2025
Q2 		$417K Buy
8,577
+5,205
+154% +$201K ﹤0.01% 1806
2025
Q1 		$115K Sell
3,372
-4,048
-55% -$172K ﹤0.01% 2254
2024
Q4 		$292K Buy
7,420
+1,622
+28% +$76.6K ﹤0.01% 1897
2024
Q3 		$272K Sell
5,798
-3,725
-39% -$189K ﹤0.01% 1864
2024
Q2 		$514K Buy
9,523
+441
+5% +$25.5K ﹤0.01% 1409
2024
Q1 		$619K Buy
9,082
+7,110
+361% +$509K 0.01% 1221
2023
Q4 		$123K Buy
1,972
+663
+51% +$36.7K ﹤0.01% 1876
2023
Q3 		$59.4K Sell
1,309
-30
-2% -$1.55K ﹤0.01% 2039
2023
Q2 		$75.2K Sell
1,339
-694
-34% -$39.4K ﹤0.01% 1949
2023
Q1 		$92K Sell
2,033
-10,697
-84% -$520K ﹤0.01% 1773
2022
Q4 		$405K Sell
12,730
-2,410
-16% -$128K 0.01% 873
2022
Q3 		$989K Buy
+15,140
New +$1.1M 0.02% 648

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NewEdge Advisors's CRSP Position: Q1 2026 in Review

NewEdge Advisors reduced its CRISPR Therapeutics (CRSP) stake by 0.14% in Q1 2026, selling an estimated $264 and leaving 3,553 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #2644.

NewEdge Advisors first reported a position in CRSP in Q3 2022 and has held it in 15 quarters since. The position peaked at $989K in Q3 2022. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • NewEdge Advisors held 3,553 shares of CRISPR Therapeutics worth $169K as of Q1 2026.
  • NewEdge Advisors sold 5 CRISPR Therapeutics shares in Q1 2026, an estimated $264.
  • CRISPR Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #2644 holding.
  • NewEdge Advisors first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • NewEdge Advisors's CRISPR Therapeutics position peaked at $989K in Q3 2022.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.